JNJ7777120

C₁₄H₁₆N₃OCl

277.75

MFCD04343337

329815408

NA.77

JNJ7777120 has been used as a histamine-4 receptor antagonist:

• to study its effects on the pro-inflammatory microglia in rats
• to study its effects on the Parkinson′s-like pathology in rat brain
• to study its effects on the histamine receptor interaction in periodontal ligament fibroblasts (PDLF)

JNJ7777120 may exhibit neuroprotective effects against ischemic brain damage. It acts as an anti-inflammatory agent to treat inflammatory diseases. JNJ7777120 is observed to reduce colonic injury, cytokine production, and neutrophil infiltration.
JNJ7777120 is a potent, selective non-imidazole H₄ histamine receptor antagonist.

This compound was developed by Johnson & Johnson. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
This compound is featured on the Histamine Receptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

100

≥98% (HPLC)

solid

white to off-white

DMSO: >20 mg/mL
H₂O: insoluble

Johnson & Johnson

room temp

CN1CCN(CC1)C(=O)c2cc3cc(Cl)ccc3[nH]2

1S/C14H16ClN3O/c1-17-4-6-18(7-5-17)14(19)13-9-10-8-11(15)2-3-12(10)16-13/h2-3,8-9,16H,4-7H2,1H3

HUQJRYMLJBBEDO-UHFFFAOYSA-N

5, 25 mg in glass bottle

GHS07

Warning

H315 - H319 - H335

P261 - P264 - P271 - P280 - P302 + P352 - P305 + P351 + P338

Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

Respiratory system

11 - Combustible Solids

WGK 3

dust mask type N95 (US), Eyeshields, Gloves